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PATIENT VIEWS OF OPIOID PHARMACOTHERAPY BIO-DELIVERY 
SYSTEMS: QUALITATIVE STUDY TO ASSIST TREATMENT DECISION 
MAKING 
 
 
ABSTRACT 
 
The technology for delivering opioid pharmacotherapy (OPT) is expanding. It is important to 
know what OPT patients think of these developments, and to find ways of enabling patients 
and clinicians to make informed decisions about which bio-delivery system to choose. We 
explored the views of current and former OPT patients with a history of heroin use to identify 
factors influencing their preferences regarding routes of OPT administration. Data were 
generated via seven focus groups conducted in London, United Kingdom. Participants (n=44) 
considered standard bio-delivery systems (liquid/linctus, tablet, injectables), emergent 
systems (implants, depot injections), and a hypothetical system (nasal sprays). Groups were 
audio-recorded, transcribed verbatim, coded using qualitative software, and analyzed 
inductively via Iterative Categorization. Participants were cautious of, but willing to consider, 
new ways of receiving OPT and they welcomed having more choice. Their preferences and 
decision-making processes were influenced by nine interconnected factors: 1. personal dislike 
of particular bio-delivery systems; 2. desired feelings following OPT administration; 3. 
perceived effectiveness of OPT bio-delivery systems; 4. concerns about side effects; 5. ability 
to control the OPT; 6. impact on daily lives; 7. concerns about OPT-related stigma; 8. need 
for psychosocial support; and 9. personal treatment goals. This complexity may make it 
difficult for patients and clinicians to evaluate the pros and cons of the expanding array of 
OPT bio-delivery systems and to arrive at clear conclusions. We therefore use the findings to 
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construct a checklist that may facilitate discussions with patients when decisions about OPT 
need to be made. 
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PUBLIC SIGNIFICANCE STATEMENT 
 
This study indicates that people who need pharmacological treatment for opioid use disorder 
welcome having increased choice about how they receive their medication (including 
liquid/linctus, tablets, implants and depot injections), but their preferences depend on a 
complex range of interconnected factors. A simple checklist is provided to help clinicians and 
their patients jointly consider and decide on the best way of receiving medication for opioid 
use disorder when faced with an increasing number of options. 
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PATIENT VIEWS OF OPIOID PHARMACOTHERAPY BIO-DELIVERY 
SYSTEMS: QUALITATIVE STUDY TO ASSIST TREATMENT DECISION 
MAKING 
 
 
BACKGROUND 
 
Opioid pharmacotherapy (OPT) is an effective and evidence-based approach to treating 
opioid dependence (Bell, 2012; NICE, 2007; SAMHSA, 2018; WHO/UNODC/UNAIDS, 
2004). There is an extensive literature evaluating and comparing different types of OPT, but 
studies are largely confined to analyses of detoxification versus maintenance, and 
assessments of specific medicines, such as methadone, buprenorphine, lofexidine, 
levomethadyl acetate (LAAM), and naltrexone (Kleber, 2007; Mattick et al., 2014; Stotts et 
al., 2009). Whilst most of this literature is based on biomedical or clinical studies, social 
scientists have used qualitative and quantitative methods to capture both treatment provider 
perspectives (e.g. Berg et al., 2009; Eversman, 2010; Larance et al., 2011; Lin et al., 2010; 
Philbin & Zhang, 2010) and patient perspectives (e.g. Anstice et al., 2009; Conner & Rosen, 
2008; Harris & McElrath, 2012; Lin et al., 2011; Nyamathi et al., 2007; Treloar et al., 2007). 
For example, numerous qualitative studies have used one-to-one interviews and focus groups 
to provide in-depth insights into patients’ views and experiences of accessing and receiving 
methadone, the most frequently prescribed treatment for opioid use disorder globally (e.g. 
Jones et al., 1994; Koester et al., 1999; Murphy & Irwin, 1992; Neale, 1998, 1999a,b; Sohler 
et al., 2013).  
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Despite this wide literature, there has been a lack of research exploring patient and provider 
views of the bio-delivery systems by which OPT medications are administered. This likely 
relates to the fact that historically almost all OPT has been consumed in liquid/linctus or 
tablet formulations, apart from rare instances of countries or clinicians providing injectable 
OPT for a minority of patients who have repeatedly failed to benefit from oral delivery 
systems (Ferri et al., 2011; Strang et al., 2015; Zador, 2001). Furthermore, many service 
providers have not had access to a choice of bio-delivery systems due to restricted licensing, 
policies, regulations and resources (at national, regional and local service levels). Recently, 
however, global increases in opioid use and poor adherence to existing opioid medications 
have generated interest and investment in the development of new OPT medications and bio-
delivery systems (Sigmon et al., 2006; Sigmon & Bigelow, 2016). This is already resulting in 
a diversification of treatment options for opioid use disorder, including rapid dispersal film or 
tablets and long-acting implant or depot injection formulations (Clinical Guidelines on Drug 
Misuse and Dependence Update 2017 Independent Expert Working Group, 2017; Sigmon et 
al., 2006; Sigmon & Bigelow, 2016). Currently, we do not know what OPT patients think of 
these new bio-delivery systems, whether they prefer them over more conventional routes of 
administration, and the reasons for their preferences. 
 
More generally still, relatively little is known about how OPT prescribing decisions are made 
when a patient and clinician meet. In the United Kingdom (UK), the introduction of national 
guidelines was followed by a two-fold overall increase in methadone and buprenorphine 
prescribing, in the direction of the guidelines’ recommendations (Strang et al., 2007). Yet, 
international data suggest that treatment decisions are more influenced by patient preferences 
than by clinical guidelines (Fischer & Stöver, 2012). The EQUATOR (European Quality 
Audit of Opioid Treatment) study, which was conducted in ten European countries, found 
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that patients mostly received the OPT treatment they requested even though less than half 
consulted physicians or pharmacies for information and most had limited knowledge of the 
available OPT options (Benyamin & Stöver, 2012; Dale-Perera et al., 2012; Fischer & 
Stöver, 2012). A survey conducted in London, UK, similarly found that patient preference 
influenced providers’ prescribing decisions, with patients preferring methadone over 
buprenorphine treatment having higher odds of receiving their preferred medication (and vice 
versa) (Ridge et al., 2009). 
 
These findings are consistent with calls to increase patient participation in treatment decision 
making (Neale, 1998; Rance & Treloar, 2015; Trujols, 2012, 2017), but fall short of 
recommendations that OPT decision making should be ‘shared’ between patients and 
clinicians (Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent 
Expert Working Group, 2017; Joosten et al., 2008; Kampman & Jarvis, 2015). Shared 
decision making has the potential to enhance patient adherence to treatment and, in turn, to 
improve patients’ health and related outcomes (Bowling & Ebrahim, 2001). However, it 
requires conversations that carefully bring together the health care professional’s knowledge 
(for example, on treatment options, risk and benefits) with the patient’s own expertise (for 
example, on their personal preferences, circumstances, goals, values and beliefs) (Bowling & 
Ebrahim, 2001; The Health Foundation, 2014). Furthermore, for OPT treatment decision 
making to be truly shared, patients must be well-informed about the available treatment 
options, able to communicate openly with clinicians, and equal partners in decision-making 
processes (Yarborough et al., 2016).  
 
With the substantial expansion of types of OPT medications and bio-delivery systems 
entering the market, it will become increasingly important to find ways of enabling patients 
Article accepted by Experimental and Clinical Psychopharmacology 
 
10 
 
and clinicians to make informed joint decisions about which bio-delivery system to choose. 
The aim of this paper is to begin this process. To this end, we explore current and former 
heroin users’ views of a range of OPT bio-delivery systems in order to identify factors 
influencing their preferences. We then use the findings to construct a checklist that clinicians 
may wish to use to facilitate discussions with patients when they are considering initiating or 
changing OPT medications.  
 
 
METHODS 
 
Our study received ethical approval from the UK NHS Research Ethics Service. During 
2017, we conducted focus groups (FGs) with current or former OPT patients with a history of 
heroin use. Focus groups were chosen over one-to-one interviews since the former are 
particularly useful when participants may feel they have little to say or existing knowledge of 
a subject is limited. This is because the group format allows participants the opportunity to 
develop and refine their ideas through interaction with others (Foster-Turner, 2009; Powell & 
Single, 1996). In this case, we were concerned that participants might struggle to articulate 
views on bio-delivery systems that they had not personally experienced or previously 
considered, and we believed that group discussions would enable them to reflect and then 
form and express opinions. 
 
Participants were recruited from drug and alcohol services, a peer support recovery service, 
and a homeless hostel in London, UK. These locations were chosen in order to ensure a mix 
of people receiving different medications, former OPT patients with no current street opioid 
use, and former OPT patients with current street opioid use. Recruitment occurred in several 
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ways: i. posters with the researchers’ contact details were displayed in the services; ii. 
researchers approached potential participants in the waiting rooms at the services; iii. workers 
and volunteers at the services encouraged service users to contact the researchers; and iv. 
participants from the earlier focus groups introduced the study to their peers. All people 
expressing interest in participating (n=76) were provided with further information about the 
study and asked to complete a basic questionnaire covering gender, age, ethnicity, substance 
use, prescribed medications, and contact details.  
 
Using data from the questionnaire, the 76 people expressing interest were first stratified based 
on their current OPT treatment status: oral linctus methadone, buprenorphine tablets, 
injectable OPT, former OPT (no current street opioids), and former OPT (current street 
opioid use). This was because we did not want to mix people on different treatments within 
FGs. Specifically, we did not want to bring people in stable treatment or currently abstinent 
into contact with people currently using street opioids in case this prompted (re)lapses. 
Equally, we did not want to bring people who were receiving oral OPT into contact with 
people receiving injectable OPT in case this prompted requests for injectable treatment 
(which is not commonly available in the UK). In addition, we stratified people by current 
treatment status as some homogeneity of group composition tends to make it easier for 
participants to engage in sharing and comparing, particularly when discussing topics that 
might be considered deviant behavior (Morgan, 2006). 
 
To avoid having more than 10 participants in a single FG (Foster-Turner, 2009), both the oral 
linctus methadone and buprenorphine tablet groups were split into two. Next, the lists of 
people for each group were reviewed to ensure that there was, in so far as possible, a 
balanced mix of men and women, age groups, ethnic backgrounds, and duration of current 
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treatment. During this process 27 people were omitted (mostly people in current receipt of 
methadone or buprenorphine), leaving 49 current or former OPT patients who were all 
contacted and invited to attend one of the following seven groups: oral liquid/linctus 
methadone (FGs 1 and 2); buprenorphine tablets (FGs 3 and 4); injectable diamorphine or 
injectable methadone (FG5); previously in receipt of OPT but now not using any opioids at 
all (FG6); and previously (but no longer) in receipt of OPT and now all using street opioids 
(FG7). Of the 49 people invited to attend a group, 44 (28 men and 16 women, aged 33-66 
years) arrived and participated on the day (3 sent apologies and 2 did not show). Additional 
details about the participants in each group (including their current street opioid use and 
current and previous OPT treatment) are shown in Table 1. 
 
Table 1 
 
All participants provided written informed consent before the start of their group and 
received £10 as a gesture of thanks at the end. Each group was facilitated by two researchers 
(CNET and RM) who used a topic guide comprising questions relating to common OPT bio-
delivery systems (liquid, tablet, injectable routes), emergent OPT bio-delivery systems 
(implants, depot injections), and a hypothetical OPT bio-delivery system (nasal sprays). 
Participants were asked to discuss any personal experiences of taking OPT via different 
routes, including what they liked and disliked about each, as well as their views on, and 
willingness to try, other ways of taking OPT. Throughout the emphasis was on the bio-
delivery system, rather than the actual drug (pharmaceutical agent) or dosage. When 
participants began to conflate these issues, the researchers gently steered the discussions back 
to the bio-delivery system. 
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Groups lasted between 41 and 63 minutes and were audio-recorded. The audio recordings 
were transcribed verbatim by a professional transcriber and coded and analysed according to 
the principles of Iterative Categorization (Neale, 2016). To this end, each participant was first 
given a unique identifier that denoted their focus group, gender and participant number within 
their group (for example: FG2, female, participant 3). Next all data were coded using the 
qualitative software programme MAXQDA (version 11). The coding frame comprised 
deductive codes derived directly from the topic guide and inductive codes emerging from the 
data. One researcher (CNET) undertook all coding to ensure consistency and transparency 
(Barbour, 2001). All coded data (with participant identifiers) were then exported from 
MAXQDA into Microsoft Word documents and analysed inductively by two of the 
researchers (CNET and JN).  
 
In the first stage of the analyses, all Word documents were reviewed line-by-line to produce 
descriptive accounts of whether and why participants liked, disliked and would be willing to 
try different OPT bio-delivery systems. Participant identifiers were retained so that it was 
possible to link all comments directly back to the individuals making them. In the second 
stage of the analyses, the descriptive findings were reviewed more analytically to extract 
factors influencing participants’ preferences across all the bio-delivery systems. Again, 
participant identifiers were retained, so that it was also possible to explore the extent to which 
the factors identified varied by FG (and therefore current treatment status) or other variables. 
Once these analyses were complete, RM reviewed the findings to check that they 
corresponded with her subjective memory of the groups. No discrepancies were identified.   
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FINDINGS 
 
Across all groups, participants generally reported that they were willing to consider receiving 
OPT in a range of ways. Indeed, they welcomed the prospect of having some choice. They 
argued that it was important to have options since opioid users have different needs and 
preferences, know their own bodies better than professionals, and have a right to decide what 
medication they take. Moreover, choice would enable them to try out different bio-delivery 
systems to discover what worked best for them personally. As one participant explained:  
 
“Not one thing suits everybody. So… even to try a couple of things and find what’s 
best for you. So, yeah, to have a choice of two, three, whatever things would be 
amazing.” (FG2, female, participant 3) 
 
Analyses indicated that participants’ preferences for OPT bio-delivery systems were 
underpinned by nine factors. These are each described below and illustrated by anonymized 
verbatim quotations. For the most part, participants considered the bio-delivery systems with 
reference to their own personal drug use and treatment histories. However, they also 
sometimes reflected on what they thought others might want or need. Although participants 
within groups often expressed different opinions about particular bio-delivery systems, the 
same discussions tended to replicate across all seven groups. Where differences between sub-
groups of participants were evident in the analyses, we document them below. 
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1. Personal dislike of particular OPT bio-delivery systems 
 
Participants in all FGs frequently voiced strong reasons why they did not want to receive 
their medication by a particular bio-delivery system, and they routinely linked these 
explanations back to their own personal experiences of both OPT and illicit drug use. 
Sometimes participants referred to physical aversions: for example, liquid OPT made them 
feel, or actually be, nauseous; they found drinking large dosages of liquid OPT physically 
uncomfortable; they had difficulty swallowing tablets; the aftertaste from tablets was too 
chalky or unpleasant; their venous access was too poor to inject medications; or sinus 
problems would make it difficult for them to use medication via a nasal spray. On other 
occasions, their dislike of a particular bio-delivery system was more psychological: for 
example, they were afraid of needles; needles reminded them of an injecting history that they 
were trying to forget; they were worried about using nasal sprays because of their 
associations with snorting drugs or because they might prompt them to snort drugs; or they 
did not like the idea of having a foreign body ‘implanted’ inside them.   
 
• “It’s just the actual liquid going down… just makes me feel sick.” (FG1, female, 
participant 2) 
• “I don’t like the idea of it [implant] actually being in your skin or under the skin. It’s 
the actual thought about it being there, under my skin, and I’d feel it.” (FG3, male, 
participant 5) 
• “The nasal spray, it reminds me of like snorting cocaine… So that would be like 
memories.” (FG4, female, participant 2) 
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2. Desired feelings following OPT administration 
 
A further key factor influencing participants’ medication preferences was how they wanted 
any OPT to make them feel. Thus, some expressed a desire for slow-release medication 
delivered by an implant or depot injection, since this would keep them feeling ‘on a level’, 
‘the same’, or ‘normal’ throughout the day for many days at a time. In contrast, others 
(mostly – but not exclusively - participants currently receiving oral linctus methadone and 
injectable formulations) emphasized that they did not want to feel constantly ‘on a plateau’, 
as this would be ‘boring’. Instead, they preferred OPT with a shorter duration of action that 
would require more frequent consumption but also allow them to feel the ebb and flow of the 
medication’s effects. Expanding upon this, several participants explained how liquid OPT in 
particular permitted them to experience mild withdrawal symptoms as the medication was 
eliminated from their system, followed by warmth and slight intoxication on further dosing. 
Meanwhile, participants who were currently prescribed injectable OPT emphasized that this 
was ‘superior’ to all other bio-delivery systems since they really ‘liked the feelings’ that the 
injected medication produced. 
 
• “I don’t like the sound of that [depot injection]… Because it means that you’re on a 
level for the whole month.” (FG6, male, participant 1) 
• “I don’t want to feel flat… I want to feel human and alive.” (FG5, male, participant 1) 
• “I like to be able to feel a bit of something, and then I like to be a bit straight too… I 
like to be a little bit stoned… very stoned… to have variations on a theme.” (FG5, 
female, participant 1) 
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3. Perceived effectiveness of OPT bio-delivery systems 
 
Participants’ views of OPT bio-delivery systems were also influenced by how effective they 
believed the medication administered would be. For example, participants in all FGs 
generally emphasized that they wanted medication to take effect or ‘kick in’ immediately. In 
this regard, short-acting injectable OPT and nasal administration were considered better than 
other bio-delivery systems. However, participants also routinely said that they wanted their 
OPT to ‘hold them’ or ‘last’ for at least 24 hours. On this latter criterion, tablets were 
considered more effective than liquids, and implants and depot injections were considered 
most effective of all. In addition, participants routinely expressed concerns about withdrawal 
symptoms if OPT proved ineffective. For example, they worried that liquids and tablets 
might not be absorbed if somebody vomited shortly after ingestion and that OPT delivered by 
nasal sprays might ‘get blown away in the wind’ or be poorly absorbed if a patient had nasal 
damage, hay fever, breathing difficulties, sinus problems, or even a cold. Several participants 
were also concerned about the abuse potential of nasal sprays, commenting that ease of 
administration might tempt people to use too much or people might remove the liquid from 
the spray container and inject it. Lastly, some expressed uncertainty about the effectiveness 
of implants and depot injections, particularly how the dose would disperse once administered 
and what would happen to the dose towards the end of the implant or depot injection. 
 
• “[The] good thing about injecting is that… it’s immediate. There’s no period of 
waiting for the medication to take effect.” (FG5, male, participant 1) 
• “That [nasal spray] sounds very tempting to me… [to just have] a quick one 
[additional dose from nasal spray].” (FG6, male, participant 2) 
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• “If you have to have it [implant] put in every month, do you end up with all these 
empty capsules inside, or do they totally dissolve?” (FG2, female, participant 2) 
 
 
4. Concerns about OPT side effects  
 
Participants from all FGs discussed the potential for negative side effects from each of the 
OPT bio-delivery systems. For example, they worried about vomiting after swallowing 
liquids; respiratory problems or harm to the nose and its membranes from nasal sprays; pain 
and vein or skin damage from injected medications; infections, haematomas or skin damage 
from implants; and increased risk of overdosing if they used street drugs ‘on top of’ an 
implant or depot injection. Additionally, there was a general concern about increased 
dependence when transitioning to any new OPT bio-delivery system, including fear of 
finding it difficult to reduce and come off OPT and becoming addicted to two substances 
rather than one. Many participants were also worried that OPT delivered by implants and 
depot injections might interact with other street drugs or medicines they were taking or make 
it difficult for them to receive pain relief if they were involved in an accident. 
 
• “Because once it [implant] is in, once it’s there, it might be difficult to remove. 
Suppose you use on top, the potential for overdose might be high.” (FG7, female, 
participant 2) 
• “Anything you keep snorting up your nose is going to… rot up your fucking inside… 
It burns… no one wants to be snorting”. (FG7, female, participant 1) 
• “[A depot injection is] a mad idea of a medication… Lots of medications interact with 
each other. So what happens if you get unwell and you’re in a hospital and it’s already 
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in you, and you might need some medication that interacts with it. It just seems really 
toxic and scary for me.” (FG6, female, participant 1) 
 
 
5. Ability to control the OPT 
 
Participants, again in all FGs, routinely reported that they liked to feel in control of their own 
OPT. This included being in control of the dose they received each day, but also the time they 
took the dose. In this respect, conventional bio-delivery systems (liquids and tablets) were 
universally preferred over long-acting systems (implants and depot injections), especially 
when liquids and tablets were prescribed as a take-home dosage. Participants were 
particularly worried about having a slow-release medication, which they could not change or 
control once injected or implanted inside them. This, they said, would make them feel 
powerless and remove any sense of autonomy or responsibility they felt for their own 
treatment. Despite this, views also differed. Thus, some reported that it was easier to manage 
a liquid than tablets as they could drink as little or as much as they needed. Others stated that 
it was difficult to measure out liquid medication precisely; consequently, they preferred 
tablets as they were easier to dose. Those receiving injectable medications often complained 
that they were being prescribed an insufficient amount for their needs and this undermined 
their ability to manage or control their medication. However, others liked the fact that they 
could take their injectable OPT home to use when it suited them. In relation to nasal sprays, 
views were mixed with some participants reporting that it would be hard to get the dosage 
right (so difficult to control) and others reporting that it would be easy to take as and when 
needed (so easy to control).  
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• “It’s easier to control yourself when it’s in tablet form… I’ve found that I’m able, 
when it’s tablet form, to leave a tablet out. And suddenly you get to the end of the 
week and you think ‘Wow - I’ve left all these tablets out’.” (FG2, female, participant 
2) 
• “It [implant] is out of question… I want to be in control, not some substance under 
my skin.” (FG4, male, participant 4) 
• “[I] take it [injectable OPT] home… do it in my own time, and without any hassle… I 
wouldn’t want to be monitored by anybody.” (FG5, male, participant 3) 
 
 
6. Impact of OPT on everyday life 
 
Participants from all FGs groups frequently reported that they wanted OPT medication to 
facilitate rather than impede their daily lives. Thus, many stated that they did not want a bio-
delivery system that required them to attend a pharmacy every day as this would limit their 
opportunities to do ‘normal’ things, such as work, go to college, travel or look after their 
children. According to these participants, extended-release medication delivered via an 
implant or depot injection was more attractive than liquid, tablet or injectable formulations 
that required daily dosing. Once the implanted or depot medication was administered, they 
welcomed the prospect of not having to use street drugs or to attend treatment services. 
Others in receipt of take-home medication reported that they did not want a bio-delivery 
system that would hamper their ability to do everyday things because it was inconvenient or 
precarious to carry around. Accordingly, they disliked liquids which they described as 
‘heavy’, ‘sticky’, ‘bulky’ and prone to spillage or leakage especially when travelling. In 
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response to this, some expressed interest in nasal spray delivery systems as they felt that these 
would be very portable and easy to use whilst ‘out and about’.  
 
• “For me, it [my preference] would be the implant… I’ll be free, practically free. Go 
on holidays when I want… All of that shit.” (FG1, female, participant 1). 
• “Workwise, it [implant] is going to help, because you don’t have to worry about 
getting to the chemist.” (FG3, male, participant 3) 
• “Because you know it [depot injection] is there. It’s good, it’s brilliant. Because you 
can get on with your life and stuff. It frees you up.” (FG2, male, participant 1) 
 
 
7. Concerns about OPT-related stigma 
 
When reflecting on the various bio-delivery systems, many participants (again all FGs) 
spontaneously discussed the stigma associated with being a heroin user and with receiving 
OPT. To help counter this, they wanted their medication delivery system to be discreet. 
Having to collect liquid or tablet OPT from a pharmacy was often described as embarrassing 
and shameful, particularly if it had to be consumed in front of other customers in the 
pharmacy shop. Many participants reported that liquid methadone was especially 
stigmatizing since it was highly visible and made them look and feel ‘different’ from other 
pharmacy customers. Tablets were generally deemed more discreet than liquids, but still 
‘humiliating’, especially if the pharmacist required them to open their mouth to demonstrate 
that pills had been swallowed. Overall, participants thought that nasal administration of OPT 
would be less conspicuous and stigmatizing than liquid and tablet OPT. Meanwhile, implants 
Article accepted by Experimental and Clinical Psychopharmacology 
 
22 
 
and depot injections were considered least stigmatizing of all given that they would be 
invisible to others once they had been fitted or administered.  
 
• “When I’ve taken my medication [tablets], they keep wanting me to open my 
mouth… I feel violated.” (FG3, male, participant 2)  
• “[Tablets] they’re less stigmatizing… In a liquid form…, everybody in the chemist 
knows… If you’re getting some tablets across the counter..., you’re much more like 
the rest of the people that are using the pharmacy.” (FG6, male, participant 4) 
• “I like it [implant] because… there’s less stigma attached to something that nobody 
can see. You don’t drink it, you don’t take it, you’re just another person, and nobody 
has to know that you’ve got that under your skin.” (FG2, female, participant 2)  
 
 
8. Perceived need for adjunctive psychosocial support 
 
As above, participants routinely reported that they liked implants and depot injections 
because they freed them from constantly having to attend pharmacies and drug services. 
Nonetheless, others - mostly those who had more recently started treatment and those who 
also reported mental health problems – said that they were happy with short-acting delivery 
systems (liquid, tablet or injectable formulations) that required regular service attendance 
because they valued the support and reassurance provided by professionals. Indeed, several 
participants explained that they would find it difficult to manage their own medication every 
day, so they wanted to be monitored. Others liked having to attend services regularly as this 
offered them social contact, alongside the routine and structure of having to go to the 
pharmacy or drug service. Indeed, a minority said that having to collect their medication daily 
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was important because it ‘got them out of the house’ and/ or provided them with the only 
social interaction they had each day. Accordingly, they did not want a slow-release 
medication that would require minimal or no professional contact once fitted or administered. 
Likewise, they did not like the idea of a nasal spray formulation that might be given to them 
in large take-home quantities without close subsequent monitoring to ensure that they were 
taking it correctly. 
 
• “I’m pissed off that I have to go [to the pharmacy]. But also at the same time it’s a 
safety net… There are some pharmacists that are really good and give you that care 
while you’re going through it, the support.” (FG4, female, participant 3) 
• “Going to the chemist on a daily basis actually gets me outside the house. Because I 
don’t go outside. I really don’t do anything. I’m clinically depressed… Can you 
believe it, I look forward to actually getting up and going to the chemist in the 
mornings?” (FG2, male, participant 5) 
• “I think there’s also a negative side of it [nasal spray]… The lack of engagement with 
services… You could give someone a month’s worth of supply… How do you know 
they’re actually taking that?... They could have relapsed, they could have gone over 
[overdosed].” (FG4, female, participant 1) 
 
 
9. Personal treatment goals 
 
Lastly, participants’ preferences for particular bio-delivery systems were influenced by their 
commitment to entering and remaining in OPT and their desire to avoid street drugs or to 
become totally abstinent. For example, some participants reported that they wanted to collect 
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and take their medication (liquid, tablet or injectable) daily to provide a ritual to replace their 
use of street drugs. In contrast, others perceived the daily routine of collecting and taking 
OPT as a negative extension of drug-taking behaviours. They therefore expressed a 
preference for long-acting OPT bio-delivery systems (implants and depot injections) that 
would help them to break rituals associated with drug use. Participants who wanted to stop 
using street opioids but could not imagine being abstinent in the near future were particularly 
interested in implants and depot injections as they liked the idea of receiving guaranteed 
stable treatment for several weeks or months. Others were conversely anxious about long-
acting formulations, stating that medication delivered in this way was not easily reversed 
once administered and could create problems if they wanted to alter the dose, use street 
drugs, or be completely drug-free.  
 
• “I have really severe PTSD [post-traumatic stress disorder], so sometimes I use [street 
drugs]… And I’m having a hit [injection of street drugs] or two, done. But I pass the 
peak… For me the peak is very bad. So that’s why something which is irreversible, 
and will keep you away for a month or two, it’s too much for me.” (FG6, male, 
participant 4) 
• “You don’t know if you’re going to get on with it [depot injection]… You could hate 
it. And then… you can’t take it out. With the implant you can [take it out], but with 
that [depot injection] you can’t…. Once you’re signed up, ‘Shit, I’m screwed for the 
next two months’.” (FG5, female, participant 2) 
• “If I wasn’t ready to get clean [be abstinent], yeah, then I would do it [have an 
implant]. But it’s releasing 8 ml in me every day, you know…  My goal is to get clean 
[be abstinent].” (FG3, male, participant 1) 
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DISCUSSION 
 
Until recently, the technology for delivering OPT has been relatively limited with options 
largely restricted to liquid and tablet formulations. As new bio-delivery systems enter the 
market, it is important to know what potential patients think of these developments, and what 
factors will influence their decisions to accept and/or adhere to new ways of taking OPT 
medication. Our findings indicate that current and former heroin users are cautious of, but 
willing to consider, new OPT bio-delivery systems and welcome the idea of having more 
choice. However, their preferences and decision-making processes are influenced by multiple 
interconnected factors. These include whether they have a pre-existing dislike of particular 
bio-delivery systems; how they want OPT to make them feel; how effective they believe the 
OPT bio-delivery system will be; whether they think that the bio-delivery system will have 
side effects; how much control they will have over the medication; how the OPT received 
will likely impact on their daily lives; whether they are concerned about the stigma of 
receiving OPT; how much psychosocial support they feel they need; and what they want to 
achieve from OPT. 
 
Our findings show notable overlap with the Treatment Satisfaction with Medicines 
Questionnaire (SATMED-Q) (Ruiz et al., 2008). SATMED-Q is a generic instrument, with 
good psychometric properties, designed for use with patients undergoing pharmacological 
treatment for any chronic disease. The first four domains of the SATMED-Q are: undesirable 
side effects of the medicine; efficacy of the medicine; convenience and ease of use of the 
medicine; and impact of the medicine on everyday life (the remaining two domains are 
medical review of the medical condition and overall opinion of the medicine and health). 
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This likeness to the SATMED-Q suggests that heroin users have similar priorities and 
concerns to other patient populations experiencing chronic health problems when it comes to 
receiving medication. Meanwhile, other issues identified by our participants may also be 
relevant to non-heroin using patient groups, particularly those prescribed opioid pain 
medications. For example, participants generally liked medication that had a rapid effect, 
addressed their symptoms for at least 24 hours without further dosing, was portable, and was 
discrete. In contrast, they worried about withdrawal symptoms, becoming dependent on 
medication, interactions with other drugs, and their ability to receive effective pain relief in 
the event of an accident (c.f. Frank et al., 2016; Penney et al., 2016).  
 
Overall, we found few differences between participants’ responses based on their current 
treatment status (sic focus group attended). This likely related to the fact that participants 
generally drew upon their diverse treatment and drug use histories when responding, but also 
because they considered what others might want or need. Reflecting this, preferences 
regarding OPT bio-delivery systems varied within FGs more than across FGs, and there were 
many issues on which participants disagreed. For example, most did not want to have to 
attend a pharmacy daily; whereas some valued daily attendance since it provided routine, 
structure, reassurance and support. Most wanted to feel in control of their own OPT, but 
expressed different views on which bio-delivery systems were easiest to control. Others, 
conversely, did not want or feel able to be in control.  
 
In short, participants did not express clear preferences for one particular bio-delivery system 
over another. Instead, they tended to like and dislike aspects of each. For example, they might 
value the discretion of implants, but worry about their side effects or irreversibility once 
administered. Equally, they might appreciate the structure and routine of collecting liquid or 
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tablet OPT from the pharmacy, but dislike the stigma of having to consume it in front of 
others. Preferences also varied depending on commitment to treatment and recovery. 
Decisions about which bio-delivery system will be most appropriate for any given individual 
will therefore reflect a wide range of contradictory and dynamic pharmaceutical, physical, 
psychological, social, and lifestyle factors.  
 
Such complexity, combined with the recent diversification of new bio-delivery systems even 
for the same pharmacological agent, is likely to make it difficult for patients and clinicians to 
evaluate the pros and cons of different routes of OPT administration and to arrive at clear 
conclusions. However, difficulty does not diminish the importance of discussing treatment 
options and sharing decision making with people receiving healthcare. Responding to each 
individual patient’s needs and circumstances at any particular point in time, and sharing 
decision making with them, is at the heart of both patient-centred medicine and person-
centred care. Patient-centred medicine seeks to focus medical attention on the individual 
patient’s needs and concerns, rather than the doctor’s (Bardes, 2012). Person-centred care is a 
broader concept that involves supporting people with healthcare needs to live independent 
and fulfilling lives by focusing on their emotional, social and practical circumstances, and not 
just their medical symptoms and clinical outcomes. People using services should be treated as 
equal partners in planning, developing and monitoring care, and care must be provided ‘with’ 
them rather than done ‘to’ or ‘for’ them (The Health Foundation, 2014). 
 
The challenges of involving people experiencing addiction as partners in treatment decision 
making have previously been documented (Fischer et al. 2007, Fischer & Neale, 2008). 
Patients may not want to be involved, they may have unrealistic expectations about treatment 
options, they may not understand the different treatment options, or they may prefer medical 
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professionals to make treatment decisions for them. Furthermore, individual clinicians’ 
willingness to involve patients will likely differ and be constrained by structural factors such 
as regulations, financial resources (including the patient’s insurance), time, competing 
priorities, and the available treatment options (Fischer & Neale, 2008). Prescribing OPT is 
already a complex process subject to bureaucracy, appointments, waiting times and 
monitoring (Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent 
Expert Working Group, 2017; Neale, 2013). We have no desire to compound this by creating 
further work or unnecessary hurdles. However, patients with opioid use disorders have a right 
to be involved in medical treatment decisions in the same way as patients with other health 
conditions (Friedrichs et al., 2016). Thus, it is incumbent on clinicians to try to facilitate this. 
 
Our findings highlight a number of issues that patients and clinicians might beneficially 
consider together when decisions about OPT bio-delivery systems need to be made, and we 
have collated these into a checklist (see Table 2). We caution, however, that the data on 
which the checklist is based derive from a single qualitative study involving just 44 current 
and former heroin users in London, UK. The study did not explicitly ask about all potential 
bio-delivery systems (for example, rapid dispersal tablets, lozenges, gum, patches or 
suppositories). Additionally, the list has been constructed without input from pharmacists, 
physicians or other treatment providers (although one of the authors is an addiction 
psychiatrist) and without reference to other contextual factors that may need to be taken into 
account, such as the broader health care system within which decisions are being made or 
individual patient factors such as co-morbidities. Given these limitations, we welcome any 
feedback (from patients, clinicians or researchers) to help develop or refine the items 
included. 
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Table 2 
 
To conclude, we call for further research, involving patients and other relevant stakeholders, 
to co-produce a more developed decision tool or algorithm that will enable shared decision 
making in respect of OPT more broadly. This might include whether or not to prescribe OPT 
at all, what medications/ pharmaceutical agents to prescribe, what dosing regimens to choose, 
over what time period to prescribe, as well as which bio-delivery systems to select. We note 
the excellent online decision tool already developed by the U.S. Department of Health and 
Human Services for people wanting information on medications in treating opioid use 
disorder (SAMSHA, 2016) and also the various national guidelines offering health 
professionals practice recommendations on evidence-based treatment approaches for opioid 
use disorder (Bruneau et al., 2018; Clinical Guidelines on Drug Misuse and Dependence 
Update 2017 Independent Expert Working Group, 2017; Gowling et al., 2014). Nonetheless, 
we suggest that there is an additional need for a tool that directly assists clinicians in their 
conversations with patients. Such a tool is likely to become increasingly important as the 
options for OPT bio-delivery systems and pharmaceutical agents expand and the number of 
treatment decisions needing to be made multiplies. 
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Table 1: Participant details  
Demographic 
characteristics 
FGa1 
Oral methadone 
(n=4) 
FG2 
Oral methadone 
(n=8) 
FG3 
Buprenorphine 
tablets (n=8) 
FG4 
Buprenorphine 
tablets (n=8) 
FG5 
Injectable OPTb 
(n=6) 
FG6 
Former OPT: no 
current street 
opioids (n=6) 
FG7 
Former OPT: 
current street 
opioid use (n=4) 
All 
(n=44) 
Gender         
Male 2 (50%) 5 (63%) 6 (75%) 5 (63%) 4 (67%) 4 (67%) 2 (50%) 28 (64%) 
Female 2 (50%) 3 (38%) 2 (25%) 3 (38%) 2 (33%) 2 (33%) 2 (50%) 16 (36%) 
         
Ethnicity         
White /White Britishc 2 4 6 6 5 4 2 29 (66%) 
Asian /Asian British 0 0 0 0 0 0 0 0 (0%) 
Black /Black British 2 2 1 0 0 2 1 8 (18%) 
Mixed or Multiple 0 1 1 1 0 0 0 3 (8%) 
Other 0 1 0 1 1 0 1 4 (8%) 
         
Age          
Mean age (range) 49 (42-59) 51 (43-58) 46 (33-55) 40 (34-47) 56 (47-66) 47 (39-58) 45 (35-53) 48 (33-66) 
         
Street opioid use         
Currently using street opioids  4 (100%) 6 (75%) 4 (50%) 2 (25%) 2 (33%) n/a 4 (100%) 22 (53%) 
Mean years of street opioid 
use (range)  
26 (22-30) 33 (25-39) 22 (2-37) 17 (0-33) 39 (27-50) n/a 22 (9-31) 26 (0-50) 
Mean age of first street opioid 
use (range) 
23 (16-33) 18 (14-22) 24 (14-31) 23 (14-35) 18 (15-27) 22 (15-32) 23 (18-26) 22 (14-35) 
         
Current treatmentd         
None 0 0 0 0 0 6 4 10 (23%) 
Buprenorphine (tablets) 0 0 8 8 0 0 0 16 (36%) 
Methadone (oral) 4 8 0 0 2 0 0 14 (32%) 
Methadone (injection) 0 0 0 0 2 0 0 2 (5%) 
Diamorphine (injection) 0 0 0 0 4 0 0 4 (9%) 
Mean years on current 
treatment (range) 
10 (2-20) 10 (0-26) 4 (0-12) 1 (0-6) 31 (3-46) n/a n/a 11 (0-46) 
         
Previous treatment         
Buprenorphine 1 3 2 0 0 4 3 13 (30%) 
Methadone 2 1 7 7 3 6 4 30 (68%) 
Naltrexone 0 0 0 0 0 1 0 1 (2%) 
Diamorphine (injection) 1 0 0 0 0 0 1 2 (5%) 
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a Focus group; b Opioid Pharmacotherapy; c 21 participants identified as ‘British’, 4 as ‘Italian’, 3 as ‘Irish’, and 1 as ‘European’; d 2 participants were prescribed a combination of opioid 
medications (injectable + oral). The denominator used for the calculation of percentages across all subjects was n=44. Because two subjects from FG5 were included in the percentages for 
‘Current treatment’ twice, the total percentage across all 44 subjects adds up to 105%.  
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Table 2: Checklist to facilitate shared decision making on OPT bio-delivery systems 
1. Does the patient have a pre-existing dislike of particular OPT bio-delivery 
systems?  
Probe: How willing is the patient to try out new ways of taking OPT? Does the 
patient have a dislike of, or concern about, any particular OPT bio-delivery system?  
 
2. How does the patient want OPT to make them feel?  
Probe: Does the patient want OPT to make them feel ‘on a level’ all of the time or 
does the patient prefer to feel changes in the medication’s effects? 
 
3. What does the patient know or understand about the effectiveness of the 
available OPT bio-delivery systems? 
Probe: How important is it to the patient that OPT has an instant/ immediate effect? 
How important is it to the patient that OPT lasts at least 24 hours? How worried is 
the patient about withdrawal symptoms? How worried is the patient about their 
absorption of OPT?  
 
4. What does the patient know or understand about side effects from the available 
OPT bio-delivery systems? 
Probe: Is the patient worried about side effects? How worried is the patient about 
becoming addicted to OPT? How worried is the patient that OPT might interact with 
other street drugs or medications they are taking, including pain relief in the event of 
an accident? 
 
5. How does the patient feel about being in control of their own OPT?  
Probe: Does the patient want to control the dose of OPT they receive each day? Does 
the patient want to control the time they take OPT each day? 
 
6. How does the patient think OPT will impact on their daily lives? 
Probe: Is the patient happy to go to the pharmacy daily? Does the patient have 
commitments (e.g. work or family) that might make it difficult to attend a pharmacy 
daily? Does the patient need OPT that is portable/ easy to carry around? 
 
7. How concerned is the patient about the stigma of receiving OPT?  
Probe: Is the patient worried about other people knowing they are taking OPT? Does 
the patient have concerns about taking OPT in a pharmacy? 
 
8. How much psychosocial support does the patient feel they need? 
Probe: Does the patient think that it will be helpful to have regular contact with 
professionals (e.g. pharmacy staff, prescriber, drug worker)? What kind of psycho-
social support and/ or monitoring does the patient desire? Is the patient worried they 
might misuse/ abuse OPT? 
 
9. What are the patient’s treatment goals? 
Probe: Does the patient think they might want to stop taking OPT over the coming 
days or weeks? Does the patient think they might want to alter their dose of OPT? 
Does the patient think they might want to use street drugs? Does the patient hope to 
be drug free/ abstinent soon? 
 
